MAP4343 receives orphan drug status

<p>Mar. 18, 2008 ( Mapreg, a biotechnology company specialized in the development of novel drugs for the treatment of central nervous system diseases, announces today that the European Commission has granted its lead compound, MAP4343, orphan drug status for the treatment of spinal cord injury. <br /> The company has entered the compound in the European Community register of orphan drugs. This decision follows a favorable opinion from the Orphan Drugs Committee of the European Medicines Evaluation Agency (EMEA)…</p>